Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the acquisition of American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction rather than general financial performance.
Material Changes
The filing details an increase in the interest of a Connected Person, Dr. K. Slaoui, in GlaxoSmithKline plc ADSs. This increase resulted from the re-investment of a dividend paid to shareholders on October 2, 2014. The transaction involved the purchase of 37.405 ADSs at a price of $45.253 per ADS on October 8, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a specific insider transaction compliant with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the total number of ADSs held by Dr. K. Slaoui following the October 8, 2014 transaction.
- Confirm the dividend reinvestment plan details applicable to the October 2, 2014 dividend payment.
- Review the full Disclosure and Transparency Rule 3.1.4R(1)(c) requirements to ensure complete compliance.